Companies Act 2006

Apollo Strategic Growth Capital II Will Redeem Its Public Shares and Will Not Consummate an Initial Business Combination

Retrieved on: 
Friday, November 10, 2023
Companies Act, Acquisition, NYSE, Cayman, Wind, Commission, Companies Act 2006, Security (finance)

Accordingly, the Company will redeem all of its outstanding Class A ordinary shares, par value $0.00025 (the “public shares”), effective as of November 28, 2023.

Key Points: 
  • Accordingly, the Company will redeem all of its outstanding Class A ordinary shares, par value $0.00025 (the “public shares”), effective as of November 28, 2023.
  • The per-share redemption price for the public shares will be approximately $10.58 (the “Redemption Amount”).
  • As of November 28, 2023, the public shares will be deemed cancelled and will represent only the right to receive the Redemption Amount.
  • Beneficial owners of public shares held in “street name” will not need to take any action in order to receive the Redemption Amount.

Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales

Retrieved on: 
Monday, December 4, 2023
Science, Public Policy, Government, Other Science, Biotechnology, Research, Pharmaceutical, Health, Courts, Registrar of Companies (India), DHR, Acquisition, NYSE, Transaction, Court order, Part, Eastern Time Zone, Scheme, Danaher Corporation, Registrar, Court, Companies Act 2006, Cryptocurrency, Abcam

The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).

Key Points: 
  • The circular in relation to the Scheme was published or made available to Scheme Shareholders on October 5, 2023 (the ‘Scheme Circular‘).
  • Abcam is pleased to announce that the Court has today issued the Court Order sanctioning the Scheme.
  • The last day of trading in Abcam ADSs on Nasdaq is expected to be December 5, 2023, with trading in Abcam ADSs on Nasdaq being suspended by 8.00 a.m. (Eastern Time) on December 6, 2023.
  • Capitalized terms used in this announcement shall, unless otherwise defined, have the same meanings as set out in the Scheme Circular.

Atento announces the successful implementation of its financial restructuring and unveils new business strategy leading the way to BTO (Business Transformation Outsourcing)

Retrieved on: 
Monday, November 27, 2023
EBITDA, Acquisition, Net promoter score, Exit, Sidley Austin, LLP, English, Business process, Synthetic media, CSAT, Business transformation, ISO, Heart, CX, System, Automation, Net, RPA, High court, ESG, Frost, Growth, NPS, AI, England and Wales, Microsoft, Customer satisfaction, Companies Act 2006, Gartner, Houlihan Lokey, Customer service, Sales, Financial services, Atena, Atento

Technology-driven transformation, such as AI and intelligent automation, will remain the backbone for delivering the best customer experience with a human touch.

Key Points: 
  • Technology-driven transformation, such as AI and intelligent automation, will remain the backbone for delivering the best customer experience with a human touch.
  • Moving forward, Atento enters a new phase in its business strategy aimed at leading the way to Business Transformation Outsourcing, boosting its competitiveness in the market, and improving its growth outlook.
  • The Company today announces the occurrence of the Restructuring Effective Date on 27 November 2023 and the successful completion of its financial restructuring, implemented by way of a UK restructuring plan pursuant to Part 26A of the Companies Act 2006 (the "Restructuring Plan").
  • The Company's business strategy going forward will pivot on three main pillars: (i) revenue diversification, (ii) driving operational excellence, and (iii) transformation.

RESIGNATION OF MR SIPHO NKOSI AS CHAIRMAN AND NON-EXECUTIVE DIRECTOR OF SASOL LIMITED

Retrieved on: 
Monday, November 13, 2023
Companies Act, Nomination, Companies Act 2006, Management, Sasol

Mr Nkosi came to the conclusion that, while he was comfortable that he would be able to comply with the conflict of interest requirements of the Companies Act, 2008 (Act No.

Key Points: 
  • Mr Nkosi came to the conclusion that, while he was comfortable that he would be able to comply with the conflict of interest requirements of the Companies Act, 2008 (Act No.
  • The Board has appointed Mr Stephen Westwell, currently non-executive and lead independent director, as pro tem Chairman of the Board of Sasol Limited, with effect from 11 November 2023.
  • Mr Westwell said: "The Board commends Mr Nkosi for the leadership he has provided to the Board leading to the determination of the Future Sasol strategy and its implementation.
  • The Board of directors thank Mr Nkosi for his dedication during his tenure as Chairman of the Board and wish him well for the future."

Broadridge Expands Shareholder Disclosure Solution to UK, Australia and Hong Kong Markets

Retrieved on: 
Thursday, November 9, 2023
Security (finance), NYSE, Disclosure, SRD II, Companies Act 2006, Corporation, API, Digital transformation, Rural sociology, SRD, Workflow, Investment, Corporations Act 2001, Automation, Property management, Fintech, Broadridge Financial Solutions

NEW YORK and LONDON and HONG KONG and SYDNEY, Nov. 9, 2023 /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE:BR), a global Fintech leader, today announced the further expansion of its Shareholder Disclosure solution to meet the specific regulatory requirements in the UK, Australia and Hong Kong markets. The solution is operating live in all three markets.

Key Points: 
  • The extension of Broadridge's Shareholder Disclosure solution highlights its continued commitment to increasing transparency, driving automation through digitization and supporting customers' shareholder disclosure obligations
    NEW YORK and LONDON and HONG KONG and SYDNEY, Nov. 9, 2023 /PRNewswire/ -- Broadridge Financial Solutions, Inc. (NYSE:BR), a global Fintech leader, today announced the further expansion of its Shareholder Disclosure solution to meet the specific regulatory requirements in the UK, Australia and Hong Kong markets.
  • "Our latest service expansion allows financial intermediaries to meet their shareholder disclosure obligations in the UK, Australia and Hong Kong.
  • The UK, Australia and Hong Kong have specific disclosure requirements: UK Section 793 (Companies Act 2006), Australia Section 672 (Corporations Act 2001) and Hong Kong Section 329 (Securities and Futures Ordinance).
  • Broadridge's Shareholder Disclosure solution can now support firms needing to adhere to these regulations and seamlessly process their disclosure requests through one centralized platform.

EQS-News: SYNLAB AG publishes Joint Reasoned Statement on public acquisition offer by Cinven

Retrieved on: 
Tuesday, November 7, 2023
Companies Act 2006, Financial Oversight and Management Board for Puerto Rico, Acquisition, Reason, Supervision, Section 27 of the Canadian Charter of Rights and Freedoms, Environment, Supervisory board, FSE, Synlab Group, CET, Management, Security (finance), Audit, Property management, Financial adviser, Cinven

Management Board and Supervisory Board of SYNLAB AG published their Joint Reasoned Statement, in which they make a neutral statement.

Key Points: 
  • Management Board and Supervisory Board of SYNLAB AG published their Joint Reasoned Statement, in which they make a neutral statement.
  • The Boards abstain from a recommendation to the SYNLAB Shareholders whether to accept or decline the Offer.
  • SYNLAB AG (“SYNLAB” or the “Company”, FSE: SYAB), the leader in medical diagnostic services and specialty testing in Europe, announces that pursuant to the German Securities Acquisition and Takeover Act (WpÜG), the Management Board and Supervisory Board of SYNLAB AG today issued their Joint Reasoned Statement on the public acquisition offer (the “Offer”) by Ephios Luxembourg S.à r.l.
  • Shareholders of SYNLAB AG should therefore carefully read the entire Reasoned Statement of the Management Board and the Supervisory Board.

Shell plc publishes third quarter 2023 press release

Retrieved on: 
Thursday, November 2, 2023
Carbon, Companies Act 2006, NCI, Act, Shell plc, Shell, Registrar, Coronavirus, EBITDA, Disclosure, GAAP, Acquisition, Developed country, Arrangement, Nationalization, Bank statement, Risk, COVID-19, Divestment, Pandemic, Net, Climate change, Annual report, Movement, Natural gas, Bank, Audit

The companies in which Shell plc directly and indirectly owns investments are separate legal entities.

Key Points: 
  • The companies in which Shell plc directly and indirectly owns investments are separate legal entities.
  • In this announcement "Shell", "Shell Group" and "Group" are sometimes used for convenience where references are made to Shell plc and its subsidiaries in general.
  • Likewise, the words "we", "us" and "our" are also used to refer to Shell plc and its subsidiaries in general or to those who work for them.
  • "Subsidiaries", "Shell subsidiaries" and "Shell companies" as used in this announcement refer to entities over which Shell plc either directly or indirectly has control.

Eisai: Notice of Absorption-Type Merger (Simplified Merger/Short-Form Merger) of KAN Research Institute, Inc.

Retrieved on: 
Wednesday, October 4, 2023
Executive, Effective date, Tripura Merger Agreement, Disclosure, Research, Brain, Antibody, Organization, Acquisition, Patient, Deep, Companies Act, Drug discovery, Biology, R, Companies Act 2006, Disease, Pharmaceutical industry, Airline, Security (finance), Mergers and acquisitions, Eisai

In October 2022, the Company group's research and development (R&D) organization transitioned to the Deep Human Biology Learning (DHBL) drug discovery and development.

Key Points: 
  • In October 2022, the Company group's research and development (R&D) organization transitioned to the Deep Human Biology Learning (DHBL) drug discovery and development.
  • Through this merger, Eisai will further deepen it's understanding of human biology, while KAN Research Institute will continue to contribute tothe innovative creation as a major base of drug discovery research of the Company.
  • The Merger is an absorption-type merger with the Company as the surviving company and KAN Research Institute as the absorbed company which dissolves as a result of the Merger.
  • Since the Company holds all shares in KAN Research Institute, no consideration will be provided upon the Merger.

Grindrod Shipping Holdings Ltd. Announces Effective Date of the Proposed Capital Reduction and Notice of the Record Date and the Cash Distribution Date for the Proposed Capital Reduction

Retrieved on: 
Friday, September 29, 2023
ACRA, Date, Capital, JSE, EGM, USD, Acquisition, Notice, Companies Act, Companies Act 2006, Cryptocurrency, Bank

Unless otherwise defined, all capitalised terms and references used herein shall bear the same meaning ascribed to them in the Notice.

Key Points: 
  • Unless otherwise defined, all capitalised terms and references used herein shall bear the same meaning ascribed to them in the Notice.
  • With the lodgement of the aforesaid documents, the Proposed Capital Reduction will take effect as of September 29, 2023.
  • These agreements are subject to customary closing conditions with an estimated closing date of October 3, 2023.
  • The capital distribution to be distributed by the Company is regarded as a “capital distribution” and is not subject to any tax in Singapore.

EQS-News: SYNLAB AG: SYNLAB enters into investment agreement relating to a public acquisition offer by Cinven

Retrieved on: 
Friday, September 29, 2023
Financial Oversight and Management Board for Puerto Rico, Channel, CET, North, D2C, XETRA, FSE, Ontario Teachers' Pension Plan, Qatar Investment Authority, Federal Financial Supervisory Authority, Novo Holdings A/S, Acquisition, Offer, Supervisory board, Environment, Companies Act 2006, 2021 German federal election, Security (finance), Cryptocurrency, Cinven

The SYNLAB Management Board and Supervisory Board know Cinven well as a trusted and supportive long-standing shareholder and anticipate a good further cooperation.

Key Points: 
  • The SYNLAB Management Board and Supervisory Board know Cinven well as a trusted and supportive long-standing shareholder and anticipate a good further cooperation.
  • Both will carefully review the offer document following its publication and will then issue their reasoned statement on the adequacy of the Offer.
  • In the investment agreement, Cinven commits to support the strategic ambitions of SYNLAB to strengthen its position as an international leader in medical diagnostic services and specialty testing.
  • Cinven does not intend to seek or enter into a domination and profit and loss transfer agreement (DPLTA) with SYNLAB.